ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis

Louie, K. S.*; Seigneurin, A.; Cathcart, P.; Sasieni, P.
Annals of Oncology2015-5DOI: 10.1093/annonc/mdu525
135被引3阅读
引用收藏
分享

摘要

Background: Despite the extensive development of risk prediction models to aid patient decision-making on prostate screening, it is unknown whether these models could improve predictive accuracy of PSA testing to detect prostate cancer (PCa). The objective of this study was to perform a systematic review to identify PCa risk models and to assess the model's performance to predict PCa by conducting a meta-analysis. Design: A systematic literature search of Medline was conducted to identify PCa predictive risk models that used at least two variables, of which one of the variables was prostate-specific antigen (PSA) level. Model performance (discrimination and calibration) was assessed. Prediction models validated in >= 5 study populations and reported area under the curve (AUC) for prediction of any or clinically significant PCa were eligible for meta-analysis. Summary AUC and 95% CIs were calculated using a random-effects model. Results: The systematic review identified 127 unique PCa prediction models; however, only six models met study criteria for meta-analysis for predicting any PCa: Prostataclass, Finne, Karakiewcz, Prostate Cancer Prevention Trial (PCPT), Chun, and the European Randomized Study of Screening for Prostate Cancer Risk Calculator 3 (ERSPC RC3). Summary AUC estimates show that PCPT does not differ from PSA testing (0.66) despite performing better in studies validating both PSA and PCPT. Predictive accuracy to discriminate PCa increases with Finne (AUC = 0.74), Karakiewcz (AUC = 0.74), Chun (AUC = 0.76) and ERSPC RC3 and Prostataclass have the highest discriminative value (AUC = 0.79), which is equivalent to doubling the sensitivity of PSA testing (44% versus 21%) without loss of specificity. The discriminative accuracy of PCPT to detect clinically significant PCa was AUC = 0.71. Calibration measures of the models were poorly reported. Conclusions: Risk prediction models improve the predictive accuracy of PSA testing to detect PCa. Future developments in the use of PCa risk models should evaluate its clinical effectiveness in practice.

学科与关键词

关键词
prostate cancerscreeningrisk prediction modelsrisk calculatorsmeta-analysis
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Annals of Oncology
发表日期
2015-05
卷期
第 26 卷, 第 5 期
页码
848-864
DOI
10.1093/annonc/mdu525
语言
ENGLISH
期刊收录
SCIE
期刊等级
Q1
成果收录
SCIE
资助标注
NHS Cancer Screening Programmes, Public Health England; Cancer Research UK Population Research Postdoctoral Fellowship Grant [C41733/A15037]; Cancer Research UK Population Research Programme Grant [C8162/A16892]

作者

  • L

    Louie, K. S. (通讯) (第一作者)

  • S

    Seigneurin, A.

查看全部 4 位作者收起作者
  • C

    Cathcart, P.

  • S

    Sasieni, P.

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417